Product Description
Lyvelsa 10 mg Tablet is a prescription medicine containing Finerenone, a non-steroidal mineralocorticoid receptor antagonist (ns-MRA). It is primarily indicated for adults with chronic kidney disease (CKD) associated with type 2 diabetes mellitus to slow disease progression and reduce cardiovascular risks.
Finerenone works by selectively blocking mineralocorticoid receptors involved in inflammation and fibrosis, two key processes that contribute to kidney damage and heart complications in diabetic patients. Unlike traditional steroidal MRAs, Finerenone offers targeted receptor activity with improved tissue selectivity, resulting in better renal and cardiovascular protection.
Lyvelsa 10 mg Tablet helps in reducing albuminuria, delaying decline in kidney function, and lowering the risk of heart failure, myocardial infarction, and stroke in eligible patients. It is commonly prescribed as part of a comprehensive treatment plan that includes ACE inhibitors or ARBs, lifestyle management, and regular clinical monitoring.
This medicine should be taken exactly as prescribed by a healthcare professional. Regular monitoring of serum potassium levels and kidney function is essential during treatment to ensure safety and effectiveness.
Key Benefits:
- Slows progression of chronic kidney disease in type 2 diabetes
- Reduces albuminuria and kidney inflammation
- Lowers risk of cardiovascular events
- Non-steroidal MRA with selective receptor action
- Supports long-term renal and heart protection
Mechanism of Action:
Finerenone blocks mineralocorticoid receptors, preventing aldosterone-mediated inflammation and fibrosis in renal and cardiovascular tissues, thereby preserving kidney function and reducing cardiac stress.
Indications:
Chronic kidney disease associated with type 2 diabetes mellitus
Reduction of cardiovascular risk in diabetic kidney disease
Usage & Safety Information:
- For oral use only
- Use under medical supervision
- Periodic monitoring of potassium and renal parameters is recommended
- Not suitable for patients with severe hyperkalemia
